> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Boston Scientific Sales Rise Just 1.5% In Third Quarter, And It Guides To A Fourth-Quarter Drop
- URL: https://www.bullished.co/boston-scientific-sales-rise-just-1-5-in-third-quarter-and-it-guides-to-a-fourth-quarter-f2be57d7/
- Published: 2026-10-28T10:52:53.000Z
- Updated: 2026-10-28T14:50:43.000Z
- Description: The medical device maker's per-share profit fell to $0.40 from $0.51, and it forecast fourth-quarter sales down 3.0% to 1.0%.
- Author: Matteo Parrino
- Tags: Earnings, BSX, Industry: Healthcare

[Boston Scientific](https://www.bullished.co/tag/bsx/), which makes medical devices used to treat and diagnose disease, said Wednesday that third-quarter [net sales](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000066/earningsrelease%5Flive.htm?ref=bullished.co) grew only 1.5% to $5.138 billion, while profit per share fell. The company also forecast that fourth-quarter sales will decline.

## Profit slips as sales stall

The 1.5% growth was the same on a reported, operational and organic basis, the company said in its [8-K](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000066/bsx-20261028.htm?ref=bullished.co) earnings release. Net income attributable to common stockholders under standard accounting was $582 million, or $0.40 per share, against $755 million, or $0.51, a year earlier.

Adjusted EPS, which strips out certain charges, was [$0.73 versus $0.75](https://markets.ft.com/data/announce/detail?dockey=600-202610280630PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE82628-1&ref=bullished.co) a year ago. Litigation-related charges were $81 million in the quarter and restructuring net charges were $63 million; neither appeared in the year-earlier quarter's operating expenses at that size.

CEO Mike Mahoney, who is also chairman, said "This has been a challenging year for Boston Scientific" and credited global teams for working "with urgency and resilience to restore operations" after the cybersecurity incident the company first reported on August 26, 2026.

## Neuromodulation up 13.1%, urology down

By segment, [Cardiovascular sales rose 1.9%](https://markets.ft.com/data/announce/detail?dockey=600-202610280630PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE82628-1&ref=bullished.co) to $3.406 billion and MedSurg rose 0.6% to $1.733 billion. Within MedSurg, Neuromodulation climbed 13.1% on a reported basis, while Urology fell 3.2% and Endoscopy fell 0.8%.

Regionally, U.S. sales edged up 0.5%. Europe, the Middle East and Africa rose 4.4% reported, and Latin America and Canada jumped 16.0% reported, the fastest of any region. Asia-Pacific slid 0.6%.

The company also cited FDA 510(k) clearances for kidney stone and peripheral artery disease products, and the start of enrollment in a trial of its next-generation WATCHMAN Elite stroke-prevention implant.

## A forecast for shrinking sales

Boston Scientific expects fourth-quarter net sales to fall by approximately 3.0% to 1.0% on a reported and organic basis, with adjusted EPS of $0.77 to $0.79\. For the full year it now estimates adjusted EPS of $3.16 to $3.18, with net sales growth of approximately 4.25% reported and approximately 3.75% organic.

Management discusses the results with analysts on a call Wednesday at 8:00 a.m. ET.

Through nine months, adjusted EPS stands at $2.39 against $2.26 a year earlier, and the fourth-quarter range of $0.77 to $0.79 is what the full-year guidance now rests on.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BOSTON SCIENTIFIC CORP (BSX)](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000066/bsx-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit earningsrelease\_live.htm — BOSTON SCIENTIFIC CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000066/earningsrelease%5Flive.htm?ref=bullished.co) — SEC EDGAR
- [Boston Scientific announces results for third quarter 2026 – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610280630PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE82628-1&ref=bullished.co) — Financial Times

### More on Boston Scientific

- [Boston Scientific Stock Plunges 8%, Wiping Out $5.4 Billion After Cyberattack Forces Outlook Cut](https://www.bullished.co/boston-scientific-stock-plunges-8-wiping-out-5-4-billion-after-cyberattack-forces-outlook-7812b405/)
- [Boston Scientific Calls 2027 The Trough As Watchman And Heart-Rhythm Drags Persist](https://www.bullished.co/boston-scientific-calls-2027-the-trough-as-watchman-and-heart-rhythm-drags-persist-97728c31/)
- [Boston Scientific CFO: 'We Need To Rebuild Confidence In Our Forecasts'](https://www.bullished.co/boston-scientific-cfo-we-need-to-rebuild-confidence-in-our-forecasts-dc9afa59/)

[All Boston Scientific (BSX) coverage →](https://www.bullished.co/tag/bsx/)